Literature DB >> 19371746

Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine.

N Lindegger1, B M Hagen, A R Marks, W J Lederer, R S Kass.   

Abstract

Long QT syndrome variant 3 (LQT-3) is a channelopathy in which mutations in SCN5A, the gene coding for the primary heart Na(+) channel alpha subunit, disrupt inactivation to elevate the risk of mutation carriers for arrhythmias that are thought to be calcium (Ca(2+))-dependent. Spontaneous arrhythmogenic diastolic activity has been reported in myocytes isolated from mice harboring the well-characterized Delta KPQ LQT-3 mutation but the link to altered Ca(2+) cycling related to mutant Na(+) channel activity has not previously been demonstrated. Here we have investigated the relationship between elevated sarcoplasmic reticulum (SR) Ca(2+) load and induction of spontaneous diastolic inward current (I(TI)) in myocytes expressing Delta KPQ Na(+) channels, and tested the sensitivity of both to the antianginal compound ranolazine. We combined whole-cell patch clamp measurements, imaging of intracellular Ca(2+), and measurement of SR Ca(2+) content using a caffeine dump methodology. We compared the Ca(2+) content of Delta KPQ(+/-) myocytes displaying I(TI) to those without spontaneous diastolic activity and found that I(TI) induction correlates with higher sarcoplasmic reticulum (SR) Ca(2+). Both spontaneous diastolic I(TI) and underlying Ca(2+) waves are inhibited by ranolazine at concentrations that preferentially target I(NaL) during prolonged depolarization. Furthermore, ranolazine I(TI) inhibition is accompanied by a small but significant decrease in SR Ca(2+) content. Our results provide the first direct evidence that induction of diastolic transient inward current (I(TI)) in Delta KPQ(+/-) myocytes occurs under conditions of elevated SR Ca(2+) load.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19371746      PMCID: PMC2703681          DOI: 10.1016/j.yjmcc.2009.04.003

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  41 in total

1.  Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts.

Authors:  Heather Fraser; Luiz Belardinelli; Lianguo Wang; Peter E Light; Jeffrey J McVeigh; Alexander S Clanachan
Journal:  J Mol Cell Cardiol       Date:  2006-10-05       Impact factor: 5.000

2.  Altered Na+ channels promote pause-induced spontaneous diastolic activity in long QT syndrome type 3 myocytes.

Authors:  Sandra Fredj; Nicolas Lindegger; Kevin J Sampson; Peter Carmeliet; Robert S Kass
Journal:  Circ Res       Date:  2006-11-02       Impact factor: 17.367

3.  Long QT syndrome in adults.

Authors:  Andrew J Sauer; Arthur J Moss; Scott McNitt; Derick R Peterson; Wojciech Zareba; Jennifer L Robinson; Ming Qi; Ilan Goldenberg; Jenny B Hobbs; Michael J Ackerman; Jesaia Benhorin; W Jackson Hall; Elizabeth S Kaufman; Emanuela H Locati; Carlo Napolitano; Silvia G Priori; Peter J Schwartz; Jeffrey A Towbin; G Michael Vincent; Li Zhang
Journal:  J Am Coll Cardiol       Date:  2007-01-04       Impact factor: 24.094

4.  Genotype-specific onset of arrhythmias in congenital long-QT syndrome: possible therapy implications.

Authors:  Hanno L Tan; Abdennasser Bardai; Wataru Shimizu; Arthur J Moss; Eric Schulze-Bahr; Takashi Noda; Arthur A M Wilde
Journal:  Circulation       Date:  2006-11-06       Impact factor: 29.690

Review 5.  Ranolazine: a novel agent that improves dysfunctional sodium channels.

Authors:  D Q Pham; M Mehta
Journal:  Int J Clin Pract       Date:  2007-05       Impact factor: 2.503

6.  Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium.

Authors:  J C Shryock; L Belardinelli
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

Review 7.  Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.

Authors:  Charles Antzelevitch; Luiz Belardinelli; Lin Wu; Heather Fraser; Andrew C Zygmunt; Alexander Burashnikov; José M Di Diego; Jeffrey M Fish; Jonathan M Cordeiro; Robert J Goodrow; Fabiana Scornik; Guillermo Perez
Journal:  J Cardiovasc Pharmacol Ther       Date:  2004-09       Impact factor: 2.457

8.  An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes.

Authors:  Yejia Song; John C Shryock; Luiz Belardinelli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-02-29       Impact factor: 4.733

9.  Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.

Authors:  Sandra Fredj; Kevin J Sampson; Huajun Liu; Robert S Kass
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

10.  A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response.

Authors:  John R Bankston; Minerva Yue; Wendy Chung; Meghan Spyres; Robert H Pass; Eric Silver; Kevin J Sampson; Robert S Kass
Journal:  PLoS One       Date:  2007-12-05       Impact factor: 3.240

View more
  19 in total

1.  Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.

Authors:  Ehud Chorin; Dan Hu; Charles Antzelevitch; Aviram Hochstadt; Luiz Belardinelli; David Zeltser; Hector Barajas-Martinez; Uri Rozovski; Raphael Rosso; Arnon Adler; Jesaia Benhorin; Sami Viskin
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-10

2.  18β-Glycyrrhetinic acid preferentially blocks late Na current generated by ΔKPQ Nav1.5 channels.

Authors:  Yi-mei Du; Cheng-kun Xia; Ning Zhao; Qian Dong; Ming Lei; Jia-hong Xia
Journal:  Acta Pharmacol Sin       Date:  2012-05-21       Impact factor: 6.150

Review 3.  Electrophysiologic basis for the antiarrhythmic actions of ranolazine.

Authors:  Charles Antzelevitch; Alexander Burashnikov; Serge Sicouri; Luiz Belardinelli
Journal:  Heart Rhythm       Date:  2011-03-21       Impact factor: 6.343

Review 4.  Stable angina pectoris: antianginal therapies and future directions.

Authors:  Bernard R Chaitman; Abhay A Laddu
Journal:  Nat Rev Cardiol       Date:  2011-08-30       Impact factor: 32.419

5.  Ranolazine is an Effective and Safe Treatment of Adults with Symptomatic Premature Ventricular Contractions due to Triggered Ectopy.

Authors:  Gary L Murray
Journal:  Int J Angiol       Date:  2016-07-16

6.  Late sodium current contributes to diastolic cell Ca2+ accumulation in chronic heart failure.

Authors:  Nidas A Undrovinas; Victor A Maltsev; Luiz Belardinelli; Hani N Sabbah; Albertas Undrovinas
Journal:  J Physiol Sci       Date:  2010-05-19       Impact factor: 2.781

Review 7.  X-ROS signaling in the heart and skeletal muscle: stretch-dependent local ROS regulates [Ca²⁺]i.

Authors:  Benjamin L Prosser; Ramzi J Khairallah; Andrew P Ziman; Christopher W Ward; W J Lederer
Journal:  J Mol Cell Cardiol       Date:  2012-12-06       Impact factor: 5.000

8.  Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967.

Authors:  Serge Sicouri; Luiz Belardinelli; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2013-03-22       Impact factor: 6.343

Review 9.  Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspects.

Authors:  Carol Ann Remme
Journal:  J Physiol       Date:  2013-07-01       Impact factor: 5.182

10.  Ranolazine for the suppression of ventricular arrhythmia: a case series.

Authors:  Eric Yeung; Mori J Krantz; Joseph L Schuller; Rita A Dale; Mark C Haigney
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-02-17       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.